期刊文献+

dsDNA修饰Ag-Thi-nGO电极作为生物传感器检测吉非替尼

dsDNA Modified Ag-Thi-nGO Electrode as Biosensor for Detection of Gefitinib
下载PDF
导出
摘要 电化学Ag-Thionine-nGO电极的表面用鲑鱼精子双链DNA(dsDNA)修饰以检测吉非替尼(Gefitinib)靶向药物与DNA的相互作用。采用差分脉冲伏安法研究Gefitinib的电化学分析过程,并评估其与固定在电极表面的dsDNA的相互作用。操作参数优化后,峰电流与Gefitinib浓度在0.10×10-5~10.00×10-5 mol/L范围内线性关系良好。 The surface of the electrochemical Ag-Thionine-nGO electrode was modified with salmon sperm double-stranded DNA(dsDNA)to detect the interaction of Gefitinib-targeted drug with DNA.The electrochemical analysis of Gefitinib was studied by differential pulse voltammetry and its interaction with dsDNA immobilized on the electrode surface was evaluated.After the optimization of the operating parameters,the peak current and the Gefitinib concentration had a good linear relationship in the range of 0.10×10-5~10.00×10-5 mol/L.
作者 李洁 陈慧敏 张冰聪 俞家琪 程琼 LI Jie;CHEN Hui-min;ZHANG Bing-cong;YU Jia-qi;CHENG Qiong(School of Biological and Chemical Engineering,Jiaxing University,Zhejiang Jiaxing 314001,China)
出处 《广州化工》 CAS 2021年第1期27-31,共5页 GuangZhou Chemical Industry
基金 嘉兴学院校级重点大学生创新训练计划项目(85178559)。
关键词 Ag-Thionine-nGO 双链DNA生物传感器 吉非替尼 修饰电极 Ag-Thionine-nGO double-stranded DNA biosensor Gefitinib modified electrode
  • 相关文献

参考文献4

二级参考文献33

  • 1王彬,张湘茹,储大同.易瑞沙在晚期非小细胞肺癌化疗失败后的作用[J].中华肿瘤杂志,2004,26(12):742-745. 被引量:53
  • 2YARDEN Y.The EGFR family and its ligands in human cancer.signalling mechanisms and therapeutic opportunities[J].Eur J Cancer,2001,37 Suppl 4:S3-S8. 被引量:1
  • 3CELLA D,HERBST RS,LYNCH TJ,et al.Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial[J].J Clin Oncol,2005,23 (13):2946-2954. 被引量:1
  • 4KRIS MG,NATALE RB,HERBST RS,et al.Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer:a randomized trial[J].JAMA,2003,290(16):2149-2158. 被引量:1
  • 5FUKUOKA M,YANO S,GIACCONE G,et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1Trial)[J].J Clin Oncol,2003,21 (12):2237-2246. 被引量:1
  • 6PAEZ JG,JANNE PA,LEE JC,et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J].Science,2004,304(5676):1497-1500. 被引量:1
  • 7LYNCH TJ,BELL DW,SORDELLA R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2004,350(21):2129-2139. 被引量:1
  • 8BASELGA J,RISCHIN D,RANSON M,et al.Phase I safety,pharmacokinetic,and pharmacodynamic trial of ZD1839,a selective oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with five selected solid tumor types[J].J Clin Oncol,2002,20(21):4292-4302. 被引量:1
  • 9RANSON M,HAMMOND LA,FERRY D,et al.ZD1839,a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor,is well tolerated and active in patients with solid malignant tumors:results of a phase Ⅰ trial[J].J Clin Oncol,2002,20(9):2240-2250. 被引量:1
  • 10COHEN MH,WILLIAMS GA,SRIDHARA R,et al.FDA drug approval summary:gefitinib (ZD1839) (Iressa) tablets[J].Oncologist,2003,8(4):303-306. 被引量:1

共引文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部